78273-80-0O=C(CO)NCCCOc1cccc(CN2CCCCC2)c1BCCREUFCSIMJFS-UHFFFAOYSA-N78273-80-0DTXSID30228937CHEMBL4802233CHEBI:230550Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
Roxatidine
DILI Positive
DOI:10.1016/j.drudis.2019.09.022
A - Alimentary tract and metabolism;A02 - Drugs for acid related disorders;A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord);A02BA - H2-receptor antagonists;A02BA06 - Roxatidine
QA - Alimentary tract and metabolism;QA02 - Drugs for acid related disorders;QA02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord);QA02BA - H2-receptor antagonists;QA02BA06 - Roxatidine
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.
Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood.
VerwendenAnti-ulcerative.
Wird geladen…